Stratatech to expand tests of its skin tissue on pediatric burn patients
167574
post-template-default,single,single-post,postid-167574,single-format-standard,bridge-core-1.0.5,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.2,vc_responsive
 

Stratatech to expand tests of its skin tissue on pediatric burn patients

StrataGraft is human cell-based skin tissue to treat burn wounds

Stratatech to expand tests of its skin tissue on pediatric burn patients

Stratatech is starting a test of its StrataGraft skin tissue to see how well it works on children who have suffered serious burns.

It’s the first time the Madison company — a subsidiary of British-based Mallinckrodt Pharmaceuticals — will study the use of its engineered skin tissue on pediatric burn patients; up to now, only adult patients have gone through the treatment in clinical trials.

In a continuing partnership with the U.S. Department of Health and Human Services, Stratatech is getting another $26 million from Project BioShield, a program of the Biomedical Advanced Research and Development Authority (BARDA).

READ FULL STORY